海普瑞(002399.SZ)半年度實現營收31.14億元 同比增長17.09%
格隆匯8月26日丨海普瑞(002399.SZ)發佈2021年半年度報吿,實現營業收入31.14億元,同比增長17.09%;歸屬於上市公司股東的淨利潤3.38億元,歸屬於上市公司股東的扣除非經常性損益的淨利潤2.85億元;基本每股收益0.2305元。
報吿期內,公司非肝素原料藥收入首次超過50%,製劑業務板塊毛利額規模已超越原料藥業務,標誌着海普瑞肝素產業鏈往高端無菌製劑轉型的完成,集團實現營業收入31.1億元,同比增長17.09%,環比增長16.49%;銷售費用、管理費用和利息費用同比下降4.90%,3.37%,26.38%,環比下降4.28%,9.26%,3.17%;歸屬於上市公司股東的扣除非經常性損益的淨利潤2.85億元,環比增長225.70%。
2016年,公司前瞻性地決定投資位於英國劍橋的Kymab,2021年1月,Sanofi之全資子公司與包括香港海普瑞在內的Kymab全體股東簽署股權轉讓協議,收購Kymab的全部股權,收購對價首期為11億美元,以及後續不超過3.5億美元的里程碑付款。2021年4月,上述股權轉讓已完成交割,公司已收到首期轉讓價款。此次交易充分證明了公司在新藥投資領域的卓越眼光。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.